ZBH ZIMMER BIOMET HOLDINGS, INC.

CIK 0001136869 50 ready 8-Ks latest June 29, 2026, 4:02 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (2)

Ready 8-Ks 50

Latest filing June 29, 2026, 4:02 PM ET

Top materiality 0.85

Event mix earnings ×16 · debt ×13 · leadership ×7

Sentiment 12 pos · 2 neg · 36 neu

Latest earnings ▼ miss 2026-Q1

Executive change recent →

Recent 8-K filings for ZBH

Highest-materiality recent filing

Zimmer Biomet completes acquisition of Monogram Technologies for $4.04/sh plus CVRs up to $12.37

October 7, 2025, 7:59 PM ET M&A materiality 0.85 positive item 8.01 item 9.01

Each Monogram common share converted to $4.04 cash and non-tradeable CVRs worth up to $12.37 upon milestone achievement.
Acquisition adds AI-driven semi- and fully autonomous robotics for TKA; FDA 510(k) clearance March 2025, commercialization expected early 2027.

Read filing →

June 29, 2026, 4:02 PM ET debt materiality 0.45 neutral item 1.01 item 1.02 item 2.03 item 9.01

Zimmer Biomet enters $2.75B in new revolving credit facilities, terminates prior agreements

New $1.5B five-year revolver matures June 2031, with two one-year extension options.
May 27, 2026, 5:30 PM ET other materiality 0.15 neutral item 5.07 item 9.01 ◈ Shareholder Votes ×4

Zimmer Biomet annual meeting results: all directors elected, shareholder proposal rejected

All ten director nominees elected with strong support; votes ranged from 160.9M to 167.5M for.
May 12, 2026, 6:30 AM ET other material materiality 0.75 positive item 7.01 item 5.02 item 9.01

Zimmer Biomet increases FY2026 share repurchase target to $1B, up $250M from prior view

Now expects to repurchase up to $1.0B of common stock in FY2026, a $250M increase from prior assumption.
April 28, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

ZBH Q1 net sales $2.09B (+9.3% reported); adj EPS $2.09 (+15.5%); raises FY adj EPS guidance to $8.40-$8.55

Q1 net sales $2.087B, +9.3% reported, +6.8% constant currency, +2.9% organic constant currency.
April 28, 2026, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Zimmer Biomet CFO Suketu Upadhyay resigns; Paul Stellato named interim CFO

Suketu Upadhyay resigns as CFO and EVP effective April 28, 2026, to pursue a new opportunity.
February 10, 2026, 6:59 PM ET earnings materiality 0.50 neutral item 2.02 item 9.01

Zimmer Biomet reports Q4 and FY2025 results; specifics not available in filing

Press release issued February 10, 2026, for quarter and year ended December 31, 2025.
January 12, 2026, 6:59 PM ET leadership materiality 0.30 neutral item 5.02 item 9.01

Zimmer Biomet NEO Mark Bezjak resigning employment effective Jan 16, 2026

Mark Bezjak, a named executive officer in the 2025 proxy statement, resigned all officer positions effective January 16, 2026.
November 5, 2025, 6:59 PM ET earnings materiality 0.30 neutral item 2.02 item 9.01

Zimmer Biomet reports Q3 2025 results; press release attached but not provided in filing text

Filing furnishes press release under Item 2.02 for quarter ended September 30, 2025.
October 7, 2025, 7:59 PM ET M&A materiality 0.85 positive item 8.01 item 9.01

Zimmer Biomet completes acquisition of Monogram Technologies for $4.04/sh plus CVRs up to $12.37

Each Monogram common share converted to $4.04 cash and non-tradeable CVRs worth up to $12.37 upon milestone achievement.
September 4, 2025, 7:59 PM ET debt materiality 0.60 neutral item 8.01

Zimmer Biomet issues CHF 600M in two tranches of senior unsecured bonds due 2030 and 2035

CHF 210M 0.930% bonds due Sept 4, 2030 (Tranche A) and CHF 390M 1.560% bonds due Sept 4, 2035 (Tranche B) issued.
August 7, 2025, 7:59 PM ET earnings materiality 0.30 neutral item 2.02 item 9.01

Zimmer Biomet Q2 2025 earnings released; specific figures not in filing text

Press release for quarter ended June 30, 2025 issued on August 7, 2025.
July 14, 2025, 7:59 PM ET M&A materiality 0.70 positive item 7.01 item 8.01 item 9.01

Zimmer Biomet to acquire Monogram Technologies for ~$177M upfront plus CVR up to $12.37/share

Equity value ~$177M ($4.04/share cash upfront); enterprise value ~$168M.
June 30, 2025, 7:59 PM ET debt materiality 0.50 neutral item 1.01 item 1.02 item 2.03 item 9.01 ◈ Debt Financings ×2

Zimmer Biomet enters $1.5B five-year and $1.0B 364-day revolving credit facilities

Entered $1.5B five-year unsecured revolver maturing June 27, 2030, with two one-year extension options.
June 3, 2025, 7:59 PM ET other material materiality 0.55 neutral item 5.02 item 5.03 item 5.07 item 9.01 ◈ Governance Changes

ZBH shareholders approve 10M share increase to stock plan and officer exculpation

Shareholders approved amendment to 2009 Stock Incentive Plan: 10M share increase, term to 2035, independent contractors eligible.
May 27, 2025, 7:59 PM ET leadership materiality 0.55 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Zimmer Biomet appoints Kevin Thornal as Group President, Global Businesses and the Americas effective July 1, 2025

Thornal appointed to new role effective July 1; reports to CEO Ivan Tornos, leads Americas and global business units.
May 5, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Zimmer Biomet Q1 rev +1.1%; guides 2025 adj EPS down to $7.90-$8.10, rev up including Paragon 28

Q1 net sales $1.909B (+1.1% reported, +2.3% CC); GAAP EPS $0.91, adjusted EPS $1.81.
April 21, 2025, 7:59 PM ET M&A materiality 0.75 positive item 8.01 item 9.01

Zimmer Biomet completes acquisition of Paragon 28 for $13.00/share plus CVR

Closing on April 21, 2025; each Paragon 28 share converted to $13.00 cash plus up to $1.00 CVR tied to revenue milestones.
February 25, 2025, 6:59 PM ET leadership materiality 0.55 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×3

Zimmer Biomet announces Chairman Christopher Begley to retire; CEO Ivan Tornos to succeed as Chair

Christopher Begley will retire from board at May 29, 2025 annual meeting due to mandatory retirement policy.
February 19, 2025, 6:59 PM ET debt materiality 0.75 neutral item 1.01 item 2.03 item 9.01 ◈ Debt Financings ×3

Zimmer Biomet issues $1.75B in three tranches of notes; special redemption tied to Paragon 28 merger

Issued $600M 4.700% notes due 2027, $550M 5.050% notes due 2030, and $600M 5.500% notes due 2035.
February 18, 2025, 6:59 PM ET debt materiality 0.60 neutral item 1.01 item 9.01

Zimmer Biomet issues $1.75B in notes at 4.700%, 5.050%, and 5.500%

Offering includes $600M 4.700% notes due 2027, $550M 5.050% notes due 2030, and $600M 5.500% notes due 2035.
February 6, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Zimmer Biomet Q4 sales $2.02B (+4.9% CC), adj. EPS $2.31; guides FY2025 adj. EPS $8.15-$8.35

Q4 net sales $2.023B (+4.9% constant currency); Q4 adjusted diluted EPS $2.31.
January 29, 2025, 6:59 PM ET M&A materiality 0.80 positive item 7.01 item 9.01

Zimmer Biomet to acquire Paragon 28 for $1.2B enterprise value, $13/share cash plus CVR

Upfront $13.00 per share cash (~$1.1B equity); CVR up to $1.00/share if FY2026 net sales exceed $346M.
January 29, 2025, 6:59 PM ET M&A materiality 0.85 positive item 1.01 item 9.01

Zimmer Biomet to acquire Paragon 28 for $13.00 per share cash plus up to $1.00 CVR

Deal consideration: $13.00 per share cash plus Contingent Value Right (CVR) with max $1.00 payable if Paragon 28 net revenue exceeds $361M in 2026.
November 20, 2024, 6:59 PM ET debt materiality 0.60 neutral item 1.01 item 2.03 item 9.01

Zimmer Biomet issues €700M of 3.518% notes due 2032

€700M aggregate principal, 3.518% annual interest, matures Dec 15, 2032.
November 19, 2024, 6:59 PM ET debt materiality 0.60 neutral item 1.01 item 9.01

Zimmer Biomet prices €700M 3.518% notes due 2032; proceeds to repay 2024 notes

Issued €700M aggregate principal of 3.518% notes due December 15, 2032.
October 30, 2024, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01

Zimmer Biomet Q3 sales up 4.1% cc; lowers FY2024 guidance

Q3 net sales $1.824B (+4.1% cc); diluted EPS $1.23, adjusted EPS $1.74.
August 15, 2024, 7:59 PM ET debt materiality 0.50 neutral item 1.01 item 2.03 item 9.01

Zimmer Biomet issues $700M of 5.200% notes due 2034

Issued $700M aggregate principal of 5.200% notes maturing Sep 15, 2034.
August 14, 2024, 7:59 PM ET debt materiality 0.50 neutral item 1.01 item 9.01

Zimmer Biomet prices $700M of 5.200% senior notes due 2034

Issued $700M aggregate principal amount of 5.200% notes due 2034; closing August 15, 2024.
August 7, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Zimmer Biomet Q2 adjusted EPS $2.01 beats; revenue +5.6% CC; full-year guidance reaffirmed

Q2 net sales $1.942B (+5.6% constant currency); diluted EPS $1.18 GAAP, $2.01 adjusted, exceeding expectations.
August 7, 2024, 7:59 PM ET other material materiality 0.10 neutral item 8.01 item 9.01

No material event identified; filing contains only XBRL metadata

Filing text consists solely of XBRL taxonomy elements and dates, not narrative disclosure.
July 1, 2024, 7:59 PM ET debt materiality 0.50 neutral item 1.01 item 1.02 item 2.03 item 9.01

Zimmer Biomet enters new $1.5B five-year and $1.0B 364-day credit facilities

New $1.5B unsecured five-year revolving credit facility maturing June 28, 2029.
June 20, 2024, 7:59 PM ET leadership materiality 0.35 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Zimmer Biomet appoints Embecta CEO Devdatt Kurdikar to Board of Directors

Board expanded from 10 to 11 members; Devdatt Kurdikar appointed effective June 20, 2024.
May 15, 2024, 7:59 PM ET other material materiality 0.55 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×4

ZBH shareholders approve 10M-share increase to Employee Stock Purchase Plan

All ten director nominees elected; PwC ratified as independent auditor for 2024.
May 2, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Zimmer Biomet Q1 net sales $1.889B (+3.2%); adj. EPS $1.94; reiterates FY guidance

Net sales $1.889B, up 3.2% reported and 4.4% constant currency; GAAP diluted EPS $0.84, adjusted $1.94.
February 8, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Zimmer Biomet Q4 2023 net sales $1.94B (+6.3%), adj EPS $2.20; guides FY24 adj EPS $8.00-$8.15

Q4 net sales $1.94B (+6.3% reported, +6.1% CC); diluted EPS $2.01, adjusted $2.20.
January 5, 2024, 6:59 PM ET leadership materiality 0.30 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Appoints Louis A. Shapiro, former HSS CEO, to Board of Directors

Board increased from ten to eleven members; Shapiro fills new vacancy.
December 1, 2023, 6:59 PM ET debt materiality 0.50 neutral item 1.01 item 2.03 item 9.01 ◈ Material Agreements ×2◈ Debt Financings

Zimmer Biomet issues $500M of 5.350% Notes due 2028

Issued $500M aggregate principal of 5.350% Notes due December 1, 2028; interest payable semi-annually.
November 7, 2023, 6:59 PM ET earnings materiality 0.30 neutral item 2.02 item 9.01 ◈ Earnings Releases

Zimmer Biomet reports Q3 2023 results; press release details not provided in filing extract

Press release issued November 7, 2023 covering quarter ended September 30, 2023.
August 22, 2023, 7:59 PM ET leadership materiality 0.75 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×5

Zimmer Biomet appoints Ivan Tornos as CEO, Christopher Begley as Chairman; Suketu Upadhyay expands role

Bryan Hanson steps down as Chairman, President & CEO effective Aug 22, 2023; remains advisory through Aug 31.
August 1, 2023, 7:59 PM ET earnings materiality 0.50 neutral item 2.02 item 9.01 ◈ Earnings Releases

Zimmer Biomet reports Q2 2023 earnings on Aug 1, 2023; details in attached press release

Press release for quarter ended June 30, 2023 was issued on August 1, 2023.
July 10, 2023, 7:59 PM ET debt materiality 0.50 neutral item 1.01 item 1.02 item 2.03 item 9.01 ◈ Material Agreements ×4◈ Debt Financings ×2

Zimmer Biomet enters $1.5B five-year and $1B 364-day credit facilities, refinances $520M

New $1.5B five-year unsecured revolving facility matures July 7, 2028, with two one-year extension options.
June 16, 2023, 7:59 PM ET other materiality 0.10 neutral item 9.01

Zimmer Biomet files resale registration for common stock via prospectus supplement

Filing is solely for opinion of counsel regarding legality of shares being registered for resale by selling stockholders.
May 16, 2023, 7:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×4

Zimmer Biomet shareholders elect 10 directors, approve say-on-pay at annual meeting

All 10 director nominees elected with at least 161M votes For each.
May 2, 2023, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Zimmer Biomet Q1 net sales $1.831B (+10.1% reported, +13.2% CC); raises FY2023 guidance

Q1 diluted EPS $1.11 GAAP, adjusted $1.89; net earnings $232.5M GAAP, $396.8M adjusted.
February 15, 2023, 6:59 PM ET other materiality 0.00 neutral item 9.01

Zimmer Biomet files legal opinion for resale registration of common stock

Shares registered for resale by certain selling stockholders; no new issuance or operational change.
February 3, 2023, 6:59 PM ET earnings materiality 0.50 neutral item 2.02 item 9.01 ◈ Earnings Releases

Zimmer Biomet reports Q4 and FY2022 results; no figure details in filing

Company issued press release on February 3, 2023 covering Q4 and full-year 2022 financial performance.
December 14, 2022, 6:59 PM ET other materiality 0.20 neutral item 5.03 item 9.01 ◈ Governance Changes

Zimmer Biomet amends bylaws to implement Rule 14a-19 procedural requirements for director nominations

Stockholders must certify compliance with Rule 14a-19 and provide reasonable evidence no later than five business days before meeting.
November 2, 2022, 7:59 PM ET earnings materiality 0.40 neutral item 2.02 item 9.01 ◈ Earnings Releases

Zimmer Biomet reports Q3 2022 results; details in press release not provided

Filed 8-K on Nov 2, 2022, reporting Q3 2022 financial results via press release.
August 22, 2022, 7:59 PM ET debt materiality 0.40 neutral item 1.01 item 1.02 item 2.03 item 9.01

Zimmer Biomet enters $1.5B five-year and $1.0B 364-day revolving credit facilities

New $1.5B five-year unsecured revolving credit facility matures August 19, 2027, with two one-year extension options.
August 2, 2022, 7:59 PM ET earnings materiality 0.25 neutral item 2.02 item 9.01

Zimmer Biomet reports Q2 2022 results via press release; details not available in provided filing text

Press release (Exhibit 99.1) referenced but not appended; specific financial figures cannot be extracted.